Sacred Cells Research Partners, LLC Announces Worldwide, Exclusive License to Progenitor Cell Technology

Press contact:

Tory Minus

SCRP Managing Partner

tory@aim4cure.org

 

Sacred Cells Research Partners, LLC Announces Worldwide, Exclusive License to Progenitor Cell Technology

 F

OR IMMEDIATE RELEASE Birmingham, Alabama – March 2, 2015:

Sacred Cells Research Partners, LLC (SCRP), a for-profit private company and spinoff of the Alabama Institute of Medicine (AIM), today announced that it has signed a license agreement for technology related to the production of progenitor cells for use in the therapeutic treatment of spinal cord injury.

 

Sacred Cells Research Partners, LLC, a regenerative medicine discovery and development company, was established in 2013 by the Alabama Institute of Medicine (AIM) co-founders Roman Reed and Tory Minus, and is focused on developing tools for drug discovery, in-vitro diagnostics and life-science research. The proprietary methods for scalable production of neuronal progenitor cells derived from human pluripotent stem cells (hPSC), combined with Sacred Cells Research Partners’ extensive network, vast marketing and distribution knowledge, as well as financial strength, will enable the advancement of neurological repair treatment.

 

“This license provides us with the opportunity to rapidly advance our cell-based therapy into clinical development as a new approach for spinal cord injury treatment,” said Roman Reed, CEO of Sacred Cells Research Partners. Tory Minus, Vice President of Sacred Cells Research Partners added, “We intend to expand our footprint in the biotech industry by developing improved next generation therapies based upon cutting edge technologies like that licensed presently.”

 

These highly pure and well characterized hPSC-derived neuronal progenitor cells have demonstrated utility in drug discovery, toxicity screening, and neurological research programs. Launch of pre-clinical studies to further validate this technology and the value of hPSC-derived neuronal progenitor cells is expected to begin in April, in collaboration with Dr. Aileen Anderson at UC-Irvine.

 

About Sacred Cells Research Partners, (SCRP):
SCRP is a for-profit private company formed in November 2013 to develop innovative treatments for chronic disease and injury through breakthrough cellular technologies and medical devices. SCRP funds clinical research projects and establishes strategic partnerships with world-leading scientists and principal investigators in stem cell transplant therapies and regenerative medicine. Sacred Cells Research Partners is headquartered in Birmingham, AL and expects to break new ground with regard to speed and efficiency as it pursues other license agreements and expands operations to California and Texas in 2015. For more information, visit www.sacredcells.com.

About the Alabama Institute of Medicine, (AIM):
Established in April 2013, the Alabama Institute of Medicine (AIM) is a non-profit organization (501c3) committed to funding research that will lead toward treatments and cures for chronic disease and injury. AIM’s mission is simple: to undertake and support initiatives at research institutions that focus on developing new therapeutic methodologies for the treatment of all disease and injury. For more information about AIM, visit www.aim4cure.org.